[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350926-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350926-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-immune-checkpoint-molecules-in-cancers","The role of immune checkpoint molecules in cancers","","Immune checkpoint molecules regulate T cell function, sustain immune homeostasis, and enable tumor immune evasion, making them central targets in cancer immunotherapy. This review summarizes structural features and signaling mechanisms of major co-inhibitory and co-stimulatory pathways, describing their immunoregulatory functions across solid tumors and hematological malignancies. It also discusses clinical progress of immune checkpoint inhibitors, combination strategies, resistance mechanisms, and the rationale for multi-target and personalized immune modulation to optimize therapeutic outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-immune-checkpoint-molecules-in-cancers/350926/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-immune-checkpoint-molecules-in-cancers/350926.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are immune checkpoint molecules considered critical targets in cancer immunotherapy?","Question",{"text":63,"@type":64},"They regulate T cell function and immune homeostasis while facilitating tumor immune evasion, which directly affects antitumor immunity and therapeutic response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the review classify immunotherapy based on mechanisms of action?",{"text":68,"@type":64},"It distinguishes passive immunotherapy, which uses externally produced monoclonal antibodies, from active immunotherapy, which stimulates the patient’s own immune system to attack tumor cells.",{"name":70,"@type":61,"acceptedAnswer":71},"Which checkpoint pathways are emphasized in solid tumors for tumor immune evasion?",{"text":72,"@type":64},"The review highlights dysregulated PD-1/PD-L1 and CTLA-4 pathways as key mechanisms enabling immune evasion in common solid cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350926,1790196376,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Review  \nPUBLISHED 14 January 2026  \nDOI 10.3389/fimmu.2025.1674818  \nOPEN ACCESS  \nEDITED BY  \nJuan Francisco Santibanez, University of Belgrade, Serbia  \nREVIEWED BY  \nTuoen Liu,  \nWest Virginia School of Osteopathic Medicine, United States  \nMeng Fanqiao,  \nDaping Hospital, China  \n*CORRESPONDENCE  \nLewei Zhu  \n [zlwei@fsyyy.com](zlwei@fsyyy.com)[ ](zlwei@fsyyy.com)Hailin Tang  \n [tanghl@sysucc.org.cn](tanghl@sysucc.org.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 28 July 2025  \nREVISED 23 November 2025  \nACCEPTED 16 December 2025  \nPUBLISHED 14 January 2026  \nCITATION  \nZhang M, Xu J, Zheng Z, Guo Z, Wang H, Zhou M, Tang H and Zhu L (2026) The role of immune checkpoint molecules in cancers. Front. Immunol. 16:1674818 .  \ndoi: 10.3389/fimmu.2025.1674818  \nCOPYRIGHT  \n© 2026 Zhang, Xu, Zheng, Guo, Wang, Zhou, Tang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe role of immune checkpoint molecules in cancers  \nMeilan Zhang 1†, Junjie Xu 2†, Zhaokuan Zheng 3, Zhiyun Guo 1, Hao Wang 1, Mingqing Zhou 1, Hailin Tang 2* and Lewei Zhu 4*  \n1The Afﬁliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China, 2Sun Yatsen University Cancer Center (SYSUCC), Guangzhou, China, 3 Huadu District People’s Hospital of Guangzhou, Guangzhou, China, 4The First People's Hospital of Foshan (The Afﬁliated Foshan Hospital of Southern University of Science and Technology), School of Medicine, Southern University of Science and Technology, Foshan, Guangdong, China  \nImmune checkpoint molecules play a central role in regulating T cell function, maintaining immune homeostasis, and facilitating tumor immune evasion, making them critical targets in cancer immunotherapy. This review provides a comprehensive overview of the structural characteristics and signaling mechanisms of key co-inhibitory and co-stimulatory molecules, and their immunoregulatory roles in both solid tumors and hematological malignancies. Recent advances in the clinical application of immune checkpoint inhibitors, combination therapy strategies, and mechanisms of resistance are discussed. Furthermore, the importance of multi-target combinatorial approaches and personalized immune modulation is emphasized, offering valuable insights and directions for optimizing cancer immunotherapy strategies.  \nKEYWORDS  \nimmune checkpoint, T cell exhaustion, hematological malignancy, cancer, tumor microenvironment  \n1 Introduction  \nThe global incidence and mortality of cancer have been rising steadily. In 2022, there were about 20 million new cases worldwide. Nearly 9.7 million people succumbed to the disease (1, 2) . Cancer is a major public health challenge. It progresses rapidly, shows high malignancy, is difﬁcult to detect early, and has strong metastatic potential (3) . Gaining a deeper understanding of the mechanisms underlying cancer development and enhancing existing therapies are critical for improving global cancer outcomes.  \nIn recent years, immunotherapy has emerged as a central strategy in cancer treatment. It often complements surgery, chemotherapy, or radiotherapy. Its main mechanism engage and activate the immune system to recognize and eliminate tumor cells. Immunotherapies are generally classiﬁed into two types based on their modes of action: passive immunotherapy and active immunotherapy. Passive immunotherapy relies on externally produced monoclonal antibodies to target cancer cells, enhance immune responses, or  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \ninhibit tumor growth factors, thereby limiti","cbCaieALCPMcENA1","https://ap.wps.com/l/cbCaieALCPMcENA1","pdf",1134030,17,"English","# Introduction\n## Immune checkpoint molecules and cancer immunotherapy\n## Types of immunotherapy and therapeutic targets\n## Key checkpoint proteins and signaling pathways","[{\"question\":\"Why are immune checkpoint molecules considered critical targets in cancer immunotherapy?\",\"answer\":\"They regulate T cell function and immune homeostasis while facilitating tumor immune evasion, which directly affects antitumor immunity and therapeutic response.\"},{\"question\":\"How does the review classify immunotherapy based on mechanisms of action?\",\"answer\":\"It distinguishes passive immunotherapy, which uses externally produced monoclonal antibodies, from active immunotherapy, which stimulates the patient’s own immune system to attack tumor cells.\"},{\"question\":\"Which checkpoint pathways are emphasized in solid tumors for tumor immune evasion?\",\"answer\":\"The review highlights dysregulated PD-1/PD-L1 and CTLA-4 pathways as key mechanisms enabling immune evasion in common solid cancers.\"}]","The role of immune checkpoint molecules in cancers | PDF",1790091798,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8158823fe6b122e10cf2231c6c2812ae.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/402a6342fe966722a7f9ee99058b4331.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a15e590e28a5c7abfd4ae37a56ce590.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27d2277d7d1a3598d773dd34f147407e.webp",980,1385]